Context Therapeutics Inc
NASDAQ:CNTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Context Therapeutics Inc
NASDAQ:CNTX
|
US |
|
Q
|
Qantas Airways Ltd
OTC:QABSY
|
AU |
|
Metawater Co Ltd
TSE:9551
|
JP |
|
Zhe Jiang Taihua New Material Co Ltd
SSE:603055
|
CN |
|
Ningbo Water Meter Co Ltd
SSE:603700
|
CN |
|
I
|
Integrum AB
STO:INTEG B
|
SE |
|
K
|
Kelington Group Bhd
KLSE:KGB
|
MY |
|
TBS Energi Utama Tbk PT
IDX:TOBA
|
ID |
|
Forbes & Company Ltd
BSE:502865
|
IN |
|
Yoshitsu Co Ltd
NASDAQ:TKLF
|
JP |
|
Vibra Energia SA
BOVESPA:VBBR3
|
BR |
|
K
|
KohYoungTechnologyInc
KOSDAQ:098460
|
KR |
|
Algonquin Power & Utilities Corp
TSX:AQN
|
CA |
|
Z
|
ZK International Group Co Ltd
NASDAQ:ZKIN
|
CN |
|
EFG International AG
OTC:EFGIF
|
CH |
|
Nihon Jyoho Create Co Ltd
TSE:4054
|
JP |
|
E
|
Eldorado Gold Corp
NYSE:EGO
|
CA |
|
Sintex Plastics Technology Ltd
NSE:SPTL
|
IN |
|
S
|
Starward Industries SA
WSE:STA
|
PL |
|
Unity Enterprise Holdings Ltd
HKEX:2195
|
HK |
|
M
|
Maple Leaf Foods Inc
SWB:M1L
|
CA |
|
R
|
Rainbow Children's Medicare Ltd
NSE:RAINBOW
|
IN |
|
Zhejiang Starry Pharmaceutical Co Ltd
SSE:603520
|
CN |
|
A
|
Afarak Group SE
OMXH:AFAGR
|
FI |
Context Therapeutics Inc
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. The company is headquartered in Philadelphia, Pennsylvania and currently employs 7 full-time employees. The company went IPO on 2021-10-20. The firm is engaged in developing small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The Company’s clinical program for lead candidate, onapristone extended release (ONA-XR), comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR is a small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women’s cancers. Its second program, CLDN6xCD3, is an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody (bsAbs) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing Claudin 6 (CLDN6).
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. The company is headquartered in Philadelphia, Pennsylvania and currently employs 7 full-time employees. The company went IPO on 2021-10-20. The firm is engaged in developing small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The Company’s clinical program for lead candidate, onapristone extended release (ONA-XR), comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR is a small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women’s cancers. Its second program, CLDN6xCD3, is an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody (bsAbs) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing Claudin 6 (CLDN6).
